Myfenax (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myfenax, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis by suppressing immune cell activity. It is used in adult patients undergoing kidney, liver or heart transplantation and in selected cases of systemic autoimmune disease.

GNH USA supplies Myfenax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Myfenax (mycophenolate mofetil) is used in the management of immune‑mediated conditions where suppression of lymphocyte proliferation is required.

Organ transplant rejection: reduces incidence of acute and chronic rejection in kidney, liver, heart and other solid‑organ transplants. Lupus nephritis: helps achieve remission of renal inflammation and preserve kidney function in patients with systemic lupus erythematosus. Other autoimmune disorders: provides immunosuppression for conditions such as vasculitis or connective‑tissue disease when standard therapy is insufficient.

Myfenax may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Diarrhea or abdominal discomfort. - Headache. - Decreased appetite. - Mild infections such as upper respiratory tract infections.

Serious or Rare Side Effects: - Bone marrow suppression leading to leukopenia, anemia or thrombocytopenia. - Severe or opportunistic infections. - Hepatic toxicity or elevated liver enzymes. - Increased risk of malignancies with long‑term use. - Potential teratogenic effects and fetal loss.

When prescribing Myfenax, clinicians should consider several safety measures. - Renal function: adjust dose in patients with impaired renal clearance. - Hepatic function: monitor liver enzymes regularly. - Infection risk: screen for latent infections and advise patients to report signs of infection promptly. - Pregnancy: avoid use due to potential fetal harm; discuss contraception. - Vaccination: avoid live vaccines while on therapy. - Monitoring: perform regular complete blood count and renal laboratory tests. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Myfenax can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause uncontrolled infection. - Antacids containing aluminum or magnesium: reduce absorption of mycophenolate. - Azathioprine: additive bone marrow suppression.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate exposure. - Rifampin: may decrease mycophenolate levels. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.